Vildagliptin
- Generic Name
- Vildagliptin
- Brand Names
- Galvus, Jalra, Xiliarx
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O2
- CAS Number
- 274901-16-5
- Unique Ingredient Identifier
- I6B4B2U96P
- Background
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependen...
- Indication
Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thi...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Glycemic Durability After Metformin Failure
- Conditions
- Interventions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 450
- Registration Number
- NCT02142309
- Locations
- 🇮🇹
Department of Geriatrics and Metabolic Diseases, Naples, Italy
🇮🇹Katherine Esposito, Naples, Italy
DPP-4 Inhibition, Incretins and Islet Function
- Conditions
- Interventions
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- Lund University
- Target Recruit Count
- 24
- Registration Number
- NCT02089438
- Locations
- 🇸🇪
Clinical Research Department, Lund, Sweden
Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 95
- Registration Number
- NCT01910441
Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes
- First Posted Date
- 2013-06-21
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 287
- Registration Number
- NCT01882907
- Locations
- 🇰🇷
Dong-AUniversity Medical Center, Busan, Korea, Republic of
🇰🇷Changwon Fatima Hospital, Changwon, Korea, Republic of
🇰🇷Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin
- Conditions
- Interventions
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT01871558
- Locations
- 🇫🇷
Novartis Investigative Site, Valenciennes, France
Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-05-24
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 191
- Registration Number
- NCT01862263
- Locations
- 🇲🇽
Novartis Investigative Site, Puebla, Mexico
Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women
- Conditions
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Rio de Janeiro State University
- Target Recruit Count
- 40
- Registration Number
- NCT01827280
- Locations
- 🇧🇷
Laboratory for Clinical and Experimental Research on Vascular Biology, Rio de Janeiro, Brazil
Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Target Recruit Count
- 64
- Registration Number
- NCT01822548
- Locations
- 🇮🇹
Azienda Opedaliera-Universitaria, Parma, Italy
🇮🇹Azienda Ospedaliera-Universitaria, Parma, Italy
Effects of Vildagliptine and Glimepiride on Glucose Variability
- Conditions
- Interventions
- First Posted Date
- 2013-03-15
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT01812122
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan
- Conditions
- Interventions
- First Posted Date
- 2013-01-01
- Last Posted Date
- 2013-10-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 557
- Registration Number
- NCT01758380
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.